FidoCure®
FidoCure® Employees
14 people indexed:
-
Abigail “Abby” Hull
CVT, VTS - Clinical Operations Associate
vy69546@jn92hvx8.qss Sign up to see emailv0x8ks9@yzsj16wx.1hq Sign up to see email -
1sh7j6@kv22j35z.ql2 Sign up to see email
-
9sl27s8y@7vw4tq1t.5tg Sign up to see email
-
zya@hja92hwp.l9g Sign up to see email
-
98qkp@kx0w32v2.5zk Sign up to see email
-
2x@60052x7h.55g Sign up to see email
-
j6@al6y8wjz.l0s Sign up to see email
-
jb@0gkhzzvh.1th Sign up to see email
-
g7@l284w4tp.spb Sign up to see email
-
3ph3@1ybqhy0h.v25 Sign up to see email
-
j4g4jb3@91jqq7vp.5pv Sign up to see email
-
v322g33@58p0895t.hk2 Sign up to see email
-
qj8@4b5745lj.2jw Sign up to see email
-
6jh669@0bv6ah04.7qs Sign up to see email
FidoCure® Company Information
FidoCure®, previously known as The One Health Company, operates from Palo Alto, CA, with a remote team of 14 employees. As a participant in the Y-Combinator W18 batch, the company has established itself in the healthcare industry, specifically within healthcare services, focusing on canine cancer treatment. FidoCure® offers a personalized medicine platform that utilizes genomic testing to tailor cancer therapy for dogs, going beyond traditional chemotherapy and radiation. This approach involves analyzing the genetic makeup of cancer cells to identify mutations and suggest targeted therapies. The company has developed the world’s largest proprietary cancer data set, containing 1.7 billion data points, which supports its AI-driven precision medicine platform. FidoCure® collaborates with over 143 clinics and 180 veterinary oncologists across the United States, empowering veterinarians to offer advanced genetic sequencing and targeted treatments. Their innovative methods have benefited thousands of dogs, especially when other treatment options were limited. The effectiveness and innovation of their treatments are underscored by the publication and validation of patient results in scientific journals, highlighting FidoCure®’s commitment to transforming canine cancer care through continuous research and development.